Important Communication Regarding Sana Biotechnology CNS Program
On Nov 4, 2024, Sana announced that they would be scaling back their Neurology program to reprioritize the resources within their pipeline. This cut includes the SC379 glial progenitor cell program that was approaching the start of a Phase 1 clinical trial with some focus as a potential therapy for PMD patients.
While this news is difficult to share we are grateful to the team at Sana for advancing the program. According to the press release, “Sana will actively seek a partner or opportunity to spin out this program into a new company.” We are incredibly fortunate to have the brilliant minds of Dr. Steve Goldman, Dr. Joana Osorio and their teams committed to resuming PMD research and development as soon as possible.
The PMD Foundation will continue to engage with Drs. Goldman and Osorio and we remain steadfast in bringing our support from the PMD community throughout the transition to a new development and commercialization partner.
With continued hope and support,
The PMD Foundation